Table 3.
Baseline staging of NSD participants in the PPMI, PASADENA, and SPARK studies
| PPMI (cohort at enrollment) | PASADENA | SPARK | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Sporadic PD (N = 507) | LRRK2 PD (N = 87) | GBA PD (N = 56) | SNCA PD (N = 9) | PRKN PD (N = 2) | RBD (N = 61) | Hyposmia (N = 40) | LRRK2 NMC (N = 12) | GBA NMC (N = 11) | SNCA NMC (N = 3) | HC (N = 15) | Early PD (N = 61) | Early PD (N = 110) |
| Stage, n (%) | |||||||||||||
| 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3 (100%) | N/A | NA | NA |
| 1A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (25%) | 4 (36%) | 0 | 6 (40%) | 0 | 0 |
| 1B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (25%) | 0 | 0 | 0 | 0 | 0 |
| 2A | 2 (<1%) | 0 | 0 | 0 | 0 | 19 (31%) | 10 (25%) | 4 (33%) | 6 (55%) | 0 | 8 (53%) | 0 | 14 (13%) |
| 2B | 126 (25%) | 10 (11%) | 7 (13%) | 1 (11%) | 1 (50%) | 30 (49%) | 25 (63%) | 2 (17%) | 0 | 0 | 1 (7%) | 16 (26%) | 28 (25%) |
| 3 | 328 (65%) | 53 (61%) | 33 (59%) | 3 (33%) | 1 (50%) | 5 (8%) | 4 (10%) | 0 | 1 (9%) | 0 | 0 | 40 (66%) | 61 (55%) |
| 4 | 50 (10%) | 22 (25%) | 15 (27%) | 4 (44%) | 0 | 6 (10%) | 1 (3%) | 0 | 0 | 0 | 0 | 5 (8%) | 7 (6%) |
| 5 | 1 (<1%) | 1 (1%) | 1 (2%) | 1 (11%) | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | 0 | 1 (1%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HC Healthy controls, NMC non-manifesting carriers, PD Parkinson’s disease, RBD REM sleep behavior disorder.